TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB42800

Peptide_Name

Crabrolin-AR

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 13-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

RLPRILRKIVRRL-NH2

FASTA

>TPDB42800|Anticancer|length=13
RLPRILRKIVRRL-NH2

Formula C76H145N29O14

Absent Amino Acids ANDCEQGHMFSTWY

Common Amino Acids R

Mass 1689.17

PI 13.00

Basic Residues 6

Acidic Residues 0

Hydrophobic Residues 6

Net Charge +6

Boman Index 3.26

Hydrophobicity -0.262

Aliphatic Index 172.31

Half Life

Mammalian: 1 hour Yeast: 2 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

0

A

5

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

2

I

3

L

1

K

0

M

0

F

1

P

0

S

0

T

0

W

0

Y

1

V

Amino Acid Distribution

A: 0 R: 5 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 3 K: 1 M: 0 F: 0 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 1

Length

13

Formula

C76H145N29O14

Mass

1689.17

PI

13.00

Net Charge

+6

Boman Index

3.26

Hydrophobicity

-0.262

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Synthetic Analog of Crabrolin

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 41.31 µM

Detail Source Activity Anticancer

Activity Measurement 41.31 µM

Target

Cancer Type Lung Cancer

Cell Line H-838

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 28.78 µM

Detail Source Activity Anticancer

Activity Measurement 28.78 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 52.01 µM

Detail Source Activity Anticancer

Activity Measurement 52.01 µM

Target

Cancer Type Brain Tumor

Cell Line U-251-MG

Tissue Affected Brain

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 29.90 µM

Detail Source Activity Anticancer

Activity Measurement 29.90 µM

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 32.51 µM

Detail Source Activity Anticancer

Activity Measurement 32.51 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023